Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072302 · ClinicalTrials.gov registry record · Phase 1
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT04072302 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 86 participants.
The verdict
NCT04072302, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.
Interventions
- DRUG Placebo
- DRUG KAF156
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2017-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04072302
The ClinicalTrials.gov registry entry for NCT04072302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04072302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04072302 about?
NCT04072302 is a clinical study titled "Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model". This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.
What is the current status of trial NCT04072302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2014-09-15. Estimated completion is 2017-11-29.
What interventions are being tested in trial NCT04072302?
The interventions under investigation include: Placebo (DRUG), KAF156 (DRUG).
Who is sponsoring clinical trial NCT04072302?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.